Table 1.

Food and Drug Administration (FDA) approved PAPR inhibitors and their indications.

Drug	FDA indications	Key trials
Olaparib	Ovarian cancer • Maintenance treatment in patients with germline or somatic BRCA mutation advanced epithelial ovarian, fallopian tube or primary peritoneal cancer with response to platinum based chemotherapy • Treatment in advanced ovarian cancer with germline BRCA mutation with three or more prior lines of chemotherapy	SOLO-146SOLO-247
	Breast cancer • Germline BRCA mutated, human epidermal growth factor receptor 2 (HER-2)-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting	OlympiAD48
	Prostate cancer • Treatment in germline or somatic homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer, who have progressed following prior treatment with enzalutamide or abiraterone	PROfound49
	Pancreatic cancer • Maintenance in patients with germline BRCA mutated metastatic pancreatic adenocarcinoma, whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy	POLO23
Niraparib	Ovarian cancer • Maintenance treatment in patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapyTreatment in patients with advanced ovarian, fallopian tube, or primary peritoneal cancer treated with three or more prior chemotherapy regimens and whose cancer is associated with homologous recombination deficiency (HRD)-positive status	NOVA50QUADRA51
Rucaparib	Ovarian cancer • Maintenance treatment of recurrent epithelial, ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy • Monotherapy in patients with advanced ovarian cancer with germline or somatic BRCA mutation who have been treated with two or more lines of chemotherapy • Patients with germline or somatic BRCA mutation metastatic castration-resistant prostate cancer who have been treated with androgen receptor-directed therapy and a taxane-based chemotherapy	ARIEL 352ARIEL 253TRITON 254
Talazoparib	Breast cancer • Treatment in patients with germline BRCA mutations, HER-2 negative locally advanced or metastatic breast cancer	EMBRACA55

FDA, US Food and Drug Administration.